MET exon 14 alterations in lung cancer: Exon skipping extends half-life

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 2832-2834

  Drilon, Alexander ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CAPMATINIB; CRIZOTINIB; ONARTUZUMAB; PROTEOME; SCATTER FACTOR RECEPTOR;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; COPY NUMBER VARIATION; EXON; EXON SKIPPING; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; INTRON; LUNG CANCER; MALIGNANT TRANSFORMATION; MET GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SOMATIC MUTATION; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; LUNG TUMOR; NON SMALL CELL LUNG CANCER;

ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84975076400     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0229     Document Type: Article

References (12)

1. Tong JH, Yeung SF, Chan AWH, Chung LY, Chau SL, Lung RWM, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res 2016;22:3048-56.
2. Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet 2016;17:19-32.
3. Tuffery-Giraud S, Chambert S, Demaille J, Claustres M. Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat 1999;14:359-68.
4. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006;119:2635-41.
5. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5:850-9.
6. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-9.
7. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001;8:995-1004.
8. Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol 2016;34:794-802.
9. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol 2016;34:721-30.
10. Lee J, Ou SH, Lee JM, Kim HC, Hong M, Kim SY, et al. Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget 2015;6:28211-22.
11. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88.
12. Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842-9.